Prevention of COVID-19 with booster-dose strategy among healthy adult who received 2-dose of Coronavac using ChAdOx1 nCoV-19 vaccine. COVID-19 Vaccine, AstraZeneca Booster , Fractional low dose vaccine
Conditions
Interventions
The participant will receive vaccine ChAdOx1 0.25 mL intramuscularly.,The participant will receive vaccine ChAdOx1 0.5 mL intramuscularly.
Experimental Biological/Vaccine,Active Comparator Biological/Vaccine
Low dose ,Standard Dose
Sponsors
Health and Aging Platform, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-59 years 2. Have a history of receiving two doses of CoronaVac vaccine with 21-28 days apart. 3. Post-second dose of CoronaVac vaccine for more than 60-180 days on day of participation in study
Exclusion criteria
Exclusion criteria: 1. Received immunosuppressants within 3 months prior to participation in the study 2. Received blood or blood products within 3 months prior to participation in the study 3. Received any vaccinations within 2 weeks prior to participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-S-RBD Antibody level day 0 and 14 after vaccination BIOTEC COVID-19 IgG ELISA , sVNT for neutralizing antibody day 0 and 14 after vaccination ELISA (GenScript USA),Antigen-specific cellular immunity day 0 and 14 after vaccination ELISA | — |
Secondary
| Measure | Time frame |
|---|---|
| Reactogenicity and adverse events Day1, Day 14 Prevalence,Anti-S-RBD Antibody level day 0 and 90 after vaccination BIOTEC COVID-19 IgG ELISA,sVNT for neutralizing antibody day 0 and 90 after vaccination ELISA (GenScript USA),Antigen-specific cellular immunity day 0 and 90 after vaccination ELISA | — |
Countries
Thailand
Contacts
Public ContactNattiya Hirunkarn
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed